Screener
BioCryst Pharmaceuticals BCRX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Foreign currency translation adjustment | (27) | 702 | (89) | 1,068 |
| Unrealized loss on available for sale investments | (133) | (188) | (477) | (343) |
| Total other comprehensive (loss) income | (160) | 514 | (566) | 725 |
| Net comprehensive income (loss) | $78,235 | $5,599 | $(643,983) | $5,842 |
| Net income (loss) per common share: basic | $0.31 | $0.02 | $(2.59) | $0.02 |
| Weighted average shares of common stock outstanding: basic | 254,481 | 209,519 | 248,403 | 209,203 |
| Net income (loss) per common share: diluted | $0.30 | $0.02 | $(2.59) | $0.02 |
| Weighted average shares of common stock outstanding: diluted | 265,165 | 219,886 | 248,403 | 217,574 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- BioCryst Pharmaceuticals (BCRX) reported comprehensive income (loss), net of tax, attributable to parent of $78.24M in Q2 2026.
- How has BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 1297.3% year-over-year, from $5.6M to $78.24M.
- What is the long-term trend for BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 9.4% compound annual growth rate (CAGR), from -$183.89M to $262.98M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The sum of net income and other comprehensive income, representing the total change in equity from all sources during the period. It serves as a holistic indicator of the company's overall financial health and value creation.
Ask your AI about BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude